Papanastasiou, Evangelos, Shergill, Sukhwinder S. (2021) Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? Journal of Psychopharmacology, 35 (9). pp. 1158-1160. ISSN 0269-8811. (doi:10.1177/02698811211000773) (KAR id:96366)
|
PDF
Publisher pdf
Language: English 
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
|
Download this file (PDF/130kB) |
Preview |
| Request a format suitable for use with assistive technology e.g. a screenreader | |
| Official URL: https://doi.org/10.1177/02698811211000773 |
|
| Item Type: | Article |
|---|---|
| DOI/Identification number: | 10.1177/02698811211000773 |
| Subjects: | R Medicine |
| Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
| Funders: | European Research Council (https://ror.org/0472cxd90) |
| Depositing User: | Rachael Heller |
| Date Deposited: | 27 Sep 2022 15:07 UTC |
| Last Modified: | 05 Nov 2024 13:01 UTC |
| Resource URI: | https://kar.kent.ac.uk/id/eprint/96366 (The current URI for this page, for reference purposes) |
University of Kent Author Information
Shergill, Sukhwinder S..
| Creator's ORCID: |
 https://orcid.org/0000-0003-4928-9100
|
|---|---|
| CReDIT Contributor Roles: |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):
Altmetric
Altmetric
